Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of99mTc and188Re Theranostic Agents for Prostate Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Benchtop evaluation demonstrates synthesis of diphosphine peptide conjugates for prostate cancer, suggesting viable theranostic agents.

Novel peptide conjugates utilizing diphosphine ligands successfully coordinate technetium 99m and rhenium 188, providing dual diagnostic and therapeutic platforms.
Benchtop radiolabeling protocols establish efficient chelator conjugation to receptor-targeted peptides, enabling rapid formation of stable theranostic agents.
These targeted constructs may enable precise molecular imaging and radionuclide therapy in prostate cancer, though full in vivo preclinical evaluation is required.

Pham et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark